Specific inhibitor of Smad3 (SIS3) alleviated submandibular gland fibrosis and dysfunction after dominant duct ligation in mice
Journal of Dental Sciences · 2023-04 · 18 (2) · 865-871
DOI: 10.1016/j.jds.2023.02.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Dental Sciences, 2023-04. Verfasst von Honglin Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, …. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background/purpose: Chronic obstructive sialadenitis (COS) is a condition that severely reduced patients' quality of life. This study aimed to analyze the effects of SIS3, a specific inhibitor of small mothers against decapentaplegic 3 (SMAD3), on the submandibular gland (SMG) dysfunction, fibrosis, and inflammation. Materials and methods: The dominant duct in the SMG was ligated in mice, followed by intraperitoneal injection of SIS3 (2 mg/kg/day) or Dimethyl sulfoxide (DMSO) saline for 7 days. In the sham group, this duct was surgically identified but not ligated. Saliva flow, histological structure, fibrosis, Transforming growth factor-β1 (TGF-β)/SMAD3 signaling, and inflammatory cytokines, were analyzed.
Results
SIS3 rescued ligation-induced SMG dysfunction and improved the saliva flow rate compared to DMSO. SIS3 alleviated acinar atrophy and ductal dilation and maintained the morphology of the basal membrane. SIS3 reduces interlobular and intralobular fibrosis and collagen deposition. We observed reduced SMAD3 phosphorylation and TGF-β expression. The SIS3 group showed downregulation of np_5318 and miR-21 and upregulation of miR-29 b compared to the DMSO group. Moreover, SIS3 controlled the inflammatory cytokine release, including interleukin-6 and interleukin-1β.
Conclusion
SIS3 protected duct-ligated SMGs against fibrosis and dysfunction by inhibiting the TGF-β/SMAD3 signaling and inflammatory cytokine expression. SIS3 may serve as a promising treatment for chronic obstructive sialadenitis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
- Department of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
- Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Wang, G., Hu, M., Dai, R., Li, C., & Cao, Y. (2023). Specific inhibitor of Smad3 (SIS3) alleviated submandibular gland fibrosis and dysfunction after dominant duct ligation in mice. Journal of Dental Sciences, 18(2), 865-871. https://doi.org/10.1016/j.jds.2023.02.004
Vancouver
Li H, Wang G, Hu M, Dai R, Li C, Cao Y. Specific inhibitor of Smad3 (SIS3) alleviated submandibular gland fibrosis and dysfunction after dominant duct ligation in mice. Journal of Dental Sciences. 2023;18(2):865-871. doi:10.1016/j.jds.2023.02.004
BibTeX
@article{Li2023,
author = {Li, Honglin and Wang, Guanru and Hu, Minqi and Dai, Runnan and Li, Chunjie and Cao, Yubin},
title = {Specific inhibitor of Smad3 (SIS3) alleviated submandibular gland fibrosis and dysfunction after dominant duct ligation in mice},
journal = {Journal of Dental Sciences},
year = {2023},
volume = {18},
number = {2},
pages = {865--871},
doi = {10.1016/j.jds.2023.02.004}
}
EUVIMED